Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Nephrology
Pediatric Hematology
Questions discussed in this category
For patients with suspected complement-mediated TMA, are there specific clinical or laboratory parameters that can help guide the decision for starting empirical treatment (e.g., eculizumab) while awaiting the results of complement testing?
1 Answer available
How do you dose apixaban in patients with CrCl <30 mL/minute?
1 Answer available
Do you consider starting hydroxyurea in a patient with hemoglobin S-beta thalassemia with chronic kidney disease secondary to FSGS?
No transfusion dependence but has hemoglobin in the 8-9 g/dl range.
1 Answer available
Do you hold IV iron in the setting of active infection?
1 Answer available
Is there any role for iron chelation in a patient with iatrogenic transfusion-induced iron overload such as in patients with end-stage kidney or liver disease?
Does transplant eligibility make a difference for management?
1 Answer available
17219
12910
17407
13902
10220
Papers discussed in this category
Circulation, 2022 Nov 06
A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study.
Circulation, 2022 Nov 06
Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial.
Related Topics in Nephrology
Hematologic Malignancies
Radiation Oncology
Gynecologic Cancers
Genitourinary Cancers
Pediatric Oncology
Prostate Cancer
Medical Oncology
Lymphoma
Myeloma
Renal Cell Carcinoma